Literature DB >> 19719943

Pretreatment with Tongxinluo protects porcine myocardium from ischaemia/reperfusion injury through a nitric oxide related mechanism.

Yu-tong Cheng1, Yue-jin Yang, Hai-tao Zhang, Hai-yan Qian, Jing-lin Zhao, Xian-min Meng, Fu-liang Luo, Yi-ling Wu.   

Abstract

BACKGROUND: The traditional Chinese medicine Tongxinluo can protect myocardium against ischaemia/reperfusion injury, but the mechanism of its action is not well documented. We examined the involvement of nitric oxide in the protective role of Tongxinluo.
METHODS: Miniswine were randomized to four groups of seven: sham, control, Tongxinluo and Tongxinluo coadministration with a nitric oxide synthase inhibitor N(omega)-nitro-L-arginine (L-NNA, 10 mg/kg i.v.). Three hours after administration of Tongxinluo, the animals were anaesthetised and the left anterior descending coronary artery ligated and maintained in situ for 90 minutes followed by 3 hours of reperfusion before death. Area of no reflow and necrosis and risk region were determined pathologically by planimetry. The degree of neutrophil accumulation in myocardium was obtained by measuring myeloperoxidase activity and histological analysis. Myocardial endothelial nitric oxide synthase activity and vascular endothelial cadherin content were measured by colorimetric method and immunoblotting analysis respectively.
RESULTS: Tongxinluo significantly increased the local blood flow and limited the infarct and size of no reflow. Tongxinluo also attenuated myeloperoxidase activity and neutrophil accumulation in histological sections and maintained the level of vascular endothelial cadherin and endothelial nitric oxide synthase activity in the reflow region when compared with control group. The protection of Tongxinluo was counteracted by coadministration with L-NNA.
CONCLUSIONS: Tongxinluo may limit myocardial ischaemia and protect the heart against reperfusion injury. Tongxinluo regulates synthesis of nitric oxide by altering activity of endothelial nitric oxide synthase.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19719943

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  12 in total

Review 1.  Construction of the vessel-collateral theory and its guidance for prevention and treatment of vasculopathy.

Authors:  Yiling Wu
Journal:  Front Med       Date:  2011-06-22       Impact factor: 4.592

2.  Tongxinluo modulates cytokine secretion by cardiac microvascular endothelial cells in ischemia/reperfusion injury.

Authors:  Hehe Cui; Na Li; Xiangdong Li; Kang Qi; Qing Li; Chen Jin; Tianjie Wang; Lian Duan; Leipei Jiang; Guihao Chen; Zhigang Wang; Cong Wei; Yuejin Yang
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

3.  Phosphorylation of endothelial NOS contributes to simvastatin protection against myocardial no-reflow and infarction in reperfused swine hearts: partially via the PKA signaling pathway.

Authors:  Xiang-dong Li; Yue-jin Yang; Yong-jian Geng; Jing-lin Zhao; Hai-tao Zhang; Yu-tong Cheng; Yi-ling Wu
Journal:  Acta Pharmacol Sin       Date:  2012-06-04       Impact factor: 6.150

4.  Natural product nitric oxide chemistry: new activity of old medicines.

Authors:  Hong Jiang; Ashley C Torregrossa; Deepa K Parthasarathy; Nathan S Bryan
Journal:  Evid Based Complement Alternat Med       Date:  2012-04-02       Impact factor: 2.629

5.  Cardiac microvascular barrier function mediates the protection of Tongxinluo against myocardial ischemia/reperfusion injury.

Authors:  Kang Qi; Lujin Li; Xiangdong Li; Jinglin Zhao; Yang Wang; Shijie You; Fenghuan Hu; Haitao Zhang; Yutong Cheng; Sheng Kang; Hehe Cui; Lian Duan; Chen Jin; Qingshan Zheng; Yuejin Yang
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

6.  Inhibition of miR-128-3p by Tongxinluo Protects Human Cardiomyocytes from Ischemia/reperfusion Injury via Upregulation of p70s6k1/p-p70s6k1.

Authors:  Gui-Hao Chen; Chuan-Sheng Xu; Jie Zhang; Qing Li; He-He Cui; Xiang-Dong Li; Li-Ping Chang; Rui-Jie Tang; Jun-Yan Xu; Xia-Qiu Tian; Pei-Sen Huang; Jun Xu; Chen Jin; Yue-Jin Yang
Journal:  Front Pharmacol       Date:  2017-10-30       Impact factor: 5.810

7.  Tongxinluo attenuates reperfusion injury in diabetic hearts by angiopoietin-like 4-mediated protection of endothelial barrier integrity via PPAR-α pathway.

Authors:  Kang Qi; Xiangdong Li; Yongjian Geng; Hehe Cui; Chen Jin; Peihe Wang; Yue Li; Yuejin Yang
Journal:  PLoS One       Date:  2018-06-18       Impact factor: 3.240

8.  Add-on effect of chinese herbal medicine on mortality in myocardial infarction: systematic review and meta-analysis of randomized controlled trials.

Authors:  Vincent C H Chung; Mao Chen; Qin Ying; Wilson W S Tam; Xin Yin Wu; Polly H X Ma; Eric T C Ziea; Vivian C W Wong; Jin Ling Tang
Journal:  Evid Based Complement Alternat Med       Date:  2013-01-10       Impact factor: 2.629

9.  Chinese patent medicine tongxinluo capsule for hypertension: a systematic review of randomised controlled trials.

Authors:  Jie Wang; Xingjiang Xiong; Wei Liu
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-17       Impact factor: 2.629

10.  Cardiomyocyte-derived small extracellular vesicles can signal eNOS activation in cardiac microvascular endothelial cells to protect against Ischemia/Reperfusion injury.

Authors:  Guihao Chen; Chuansheng Xu; Thomas G Gillette; Tongyi Huang; Peisen Huang; Qing Li; Xiangdong Li; Qinfeng Li; Yu Ning; Ruijie Tang; Cunrong Huang; Yuyan Xiong; Xiaqiu Tian; Jun Xu; Junyan Xu; Liping Chang; Cong Wei; Chen Jin; Joseph A Hill; Yuejin Yang
Journal:  Theranostics       Date:  2020-09-23       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.